Skip to main content
OpenTrials

Clinical trial condition

Hypercholesterolemia, Autosomal Dominant, 3

Explore clinical trials studying Hypercholesterolemia, Autosomal Dominant, 3. Study availability and eligibility vary by location and protocol.

15 public trials 2 recruiting studies
Refine in advanced search Browse all conditions

Hypercholesterolemia, Autosomal Dominant, 3 trial results

Completed

LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

NCT01380730

Conditions
Dyslipidemias, Hypercholesterolemia, Hypercholesterolemia, Autosomal Dominant, 3, +5 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Tucson, Arizona, United States
  • Research Site Malvern, Arkansas, United States
  • Research Site Anaheim, California, United States
View all 100 locations
View Trial Details
Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels

NCT01375777

Conditions
Dyslipidemias, Hypercholesterolemia, Hypercholesterolemia, Autosomal Dominant, 3, +5 more
Locations
  • Research Site Birmingham, Alabama, United States
  • Research Site Little Rock, Arkansas, United States
  • Research Site Encinitas, California, United States
  • Research Site Inglewood, California, United States
View all 58 locations
View Trial Details
Completed

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

NCT01375764

Conditions
Dyslipidemias, Hypercholesterolemia, Hypercholesterolemia, Autosomal Dominant, 3, +5 more
Locations
  • Research Site Anaheim, California, United States
  • Research Site Mission Viejo, California, United States
  • Research Site Westlake Village, California, United States
  • Research Site Atlanta, Georgia, United States
View all 42 locations
View Trial Details
Completed

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))

NCT02729025

Conditions
Behavior, Dyslipidemias, Hypercholesterolemia, Autosomal Dominant, 3, +6 more
Locations
  • Research Site Miami, Florida, United States
  • Research Site Las Vegas, Nevada, United States
  • Research Site Mooresville, North Carolina, United States
  • Research Site Philadelphia, Pennsylvania, United States
View all 15 locations
View Trial Details
Completed

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

NCT02833844

Conditions
Behavior, Blood-Borne Infections, Communicable Diseases, +20 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Hartford, Connecticut, United States
  • Research Site Washington D.C., District of Columbia, United States
  • Research Site Washington D.C., District of Columbia, United States
View all 78 locations
View Trial Details

Related conditions